Post-approval studies (Phase 4)Ended earlyNCT02575365What this trial is testingEffect of Fingolimod on NeurodegenerationWho this might be right forCognitionBrain Volume Loss Novartis Pharmaceuticals 4
Large-scale testing (Phase 3)Study completedNCT00947752What this trial is testingSafety of New Formulation of Glatiramer AcetateWho this might be right forRelapsing Remitting Multiple Sclerosis Teva Branded Pharmaceutical Products R&D, Inc. 147
Not applicableUnknownNCT04030819What this trial is testingEffectiveness of a Schema Therapy on Anxiety in Patients With Multiple SclerosisWho this might be right forAnxiety Paris Nanterre University 106
Testing effectiveness (Phase 2)Ended earlyNCT01037907What this trial is testingOrally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)Who this might be right forRelapsing Remitting Multiple Sclerosis Boston Scientific Corporation 173
Not applicableActive Not RecruitingNCT06345157What this trial is testingITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS PatientsWho this might be right forMultiple Sclerosis, Relapsing-Remitting Novartis Pharmaceuticals 379
Large-scale testing (Phase 3)UnknownNCT02220244What this trial is testingEffect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple SclerosisWho this might be right forMultiple Sclerosis MedDay Pharmaceuticals SA 105
Testing effectiveness (Phase 2)UnknownNCT02587806What this trial is testingAutologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMSWho this might be right forMultiple Sclerosis, Relapsing-Remitting Novo Cellular Medicine Institute LLP 69
Post-approval studies (Phase 4)Study completedNCT01333501What this trial is testingFingolimod Versus Interferon Beta 1b in Cognitive SymptomsWho this might be right forMultiple Sclerosis Novartis Pharmaceuticals 151
Not applicableActive Not RecruitingNCT05925049What this trial is testingA Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)Who this might be right forMultiple Sclerosis Biogen 400
Not applicableStudy completedNCT01080014What this trial is testingCorrelation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in ArgentinaWho this might be right forMultiple Sclerosis Merck KGaA, Darmstadt, Germany 252
Not applicableStudy completedNCT01110993What this trial is testingAn Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)Who this might be right forMultiple Sclerosis, Relapsing-Remitting Merck KGaA, Darmstadt, Germany 65
Not applicableStudy completedNCT03408093What this trial is testingStudy of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1bWho this might be right forMultiple Sclerosis Bayer 120
Large-scale testing (Phase 3)Study completedNCT04115488What this trial is testingEfficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®Who this might be right forRelapsing-Remitting Multiple Sclerosis (RRMS) Polpharma Biologics S.A. 265
Not applicableStudy completedNCT06127095What this trial is testingAssess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) TreatmentsWho this might be right forMultiple Sclerosis, Relapsing-Remitting Biogen 474
Post-approval studies (Phase 4)Study completedNCT03177083What this trial is testingEvaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current TherapyWho this might be right forRelapsing Remitting Multiple Sclerosis Biogen 80
Testing effectiveness (Phase 2)Study completedNCT04002934What this trial is testingBazedoxifene Acetate as a Remyelinating Agent in Multiple SclerosisWho this might be right forMultiple SclerosisMultiple Sclerosis, Relapsing-Remitting Riley Bove, MD 63
Not applicableStudy completedNCT02277964What this trial is testingDisease Control in RRMS Transferring Treatment From Natalizumab to FingolimodWho this might be right forRelapsing Remitting Multiple Sclerosis University Hospital, Basel, Switzerland 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT06800404What this trial is testing"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"Who this might be right forRelapsing Remitting Multiple Sclerosis (RRMS)Multiple Sclerosis Hope Biosciences Research Foundation 10
Not applicableLooking for participantsNCT07292480What this trial is testingMonthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease ActivityWho this might be right forMultiple Sclerosis (MS) - Relapsing-remitting Centre Hospitalier Universitaire de Nīmes 84
Early research (Phase 1)Study completedNCT01884935What this trial is testingPK and PD Study of Natalizumab in Pediatric Subjects With RRMSWho this might be right forRelapsing-Remitting Multiple Sclerosis Biogen 13